BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19467222)

  • 1. Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells.
    Grunt TW; Wagner R; Grusch M; Berger W; Singer CF; Marian B; Zielinski CC; Lupu R
    Biochem Biophys Res Commun; 2009 Jul; 385(3):454-9. PubMed ID: 19467222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer.
    Tomek K; Wagner R; Varga F; Singer CF; Karlic H; Grunt TW
    Mol Cancer Res; 2011 Dec; 9(12):1767-79. PubMed ID: 21970855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
    Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
    Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of epidermal growth factor receptor inhibitor alone and in combination with cisplatin on growth of vulvar cancer cells.
    Kim SH; Song YC; Kim SH; Jo H; Song YS
    Ann N Y Acad Sci; 2009 Aug; 1171():642-8. PubMed ID: 19723115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells.
    Kim KK; Lee JJ; Yang Y; You KH; Lee JH
    Carcinogenesis; 2008 Apr; 29(4):704-12. PubMed ID: 18258606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75.
    Puig T; Vázquez-Martín A; Relat J; Pétriz J; Menéndez JA; Porta R; Casals G; Marrero PF; Haro D; Brunet J; Colomer R
    Breast Cancer Res Treat; 2008 Jun; 109(3):471-9. PubMed ID: 17902053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatty acid synthase regulates proliferation and migration of colorectal cancer cells via HER2-PI3K/Akt signaling pathway.
    Li N; Bu X; Tian X; Wu P; Yang L; Huang P
    Nutr Cancer; 2012 Aug; 64(6):864-70. PubMed ID: 22860766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The SDF-1alpha/CXCR4 axis induces the expression of fatty acid synthase via sterol regulatory element-binding protein-1 activation in cancer cells.
    Kim K; Kim HY; Cho HK; Kim KH; Cheong J
    Carcinogenesis; 2010 Apr; 31(4):679-86. PubMed ID: 20067991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ErbB/HER receptor protein-tyrosine kinases and cancer.
    Roskoski R
    Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
    Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM
    Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.
    Kunz C; Borghouts C; Buerger C; Groner B
    Mol Cancer Res; 2006 Dec; 4(12):983-98. PubMed ID: 17189388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT.
    Scoles DR; Pavelka J; Cass I; Tran H; Baldwin RL; Armstrong K; Karlan BY
    Gynecol Oncol; 2007 Jan; 104(1):120-8. PubMed ID: 16956650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells.
    Vazquez-Martin A; Ropero S; Brunet J; Colomer R; Menendez JA
    Oncol Rep; 2007 Oct; 18(4):973-80. PubMed ID: 17786362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases.
    Singh J; Dobrusin EM; Fry DW; Haske T; Whitty A; McNamara DJ
    J Med Chem; 1997 Mar; 40(7):1130-5. PubMed ID: 9089334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New synthetic inhibitors of fatty acid synthase with anticancer activity.
    Turrado C; Puig T; García-Cárceles J; Artola M; Benhamú B; Ortega-Gutiérrez S; Relat J; Oliveras G; Blancafort A; Haro D; Marrero PF; Colomer R; López-Rodríguez ML
    J Med Chem; 2012 Jun; 55(11):5013-23. PubMed ID: 22559865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osthole suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt/mTOR pathway.
    Lin VC; Chou CH; Lin YC; Lin JN; Yu CC; Tang CH; Lin HY; Way TD
    J Agric Food Chem; 2010 Apr; 58(8):4786-93. PubMed ID: 20218616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analyzing effects of extra-virgin olive oil polyphenols on breast cancer-associated fatty acid synthase protein expression using reverse-phase protein microarrays.
    Menendez JA; Vazquez-Martin A; Oliveras-Ferraros C; Garcia-Villalba R; Carrasco-Pancorbo A; Fernandez-Gutierrez A; Segura-Carretero A
    Int J Mol Med; 2008 Oct; 22(4):433-9. PubMed ID: 18813848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells.
    Wagner R; Stübiger G; Veigel D; Wuczkowski M; Lanzerstorfer P; Weghuber J; Karteris E; Nowikovsky K; Wilfinger-Lutz N; Singer CF; Colomer R; Benhamú B; López-Rodríguez ML; Valent P; Grunt TW
    Oncotarget; 2017 Feb; 8(7):11600-11613. PubMed ID: 28086243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of anti-proliferative lichen metabolite, protolichesterinic acid on fatty acid synthase, cell signalling and drug response in breast cancer cells.
    Bessadóttir M; Skúladóttir EÁ; Gowan S; Eccles S; Ögmundsdóttir S; Ogmundsdóttir HM
    Phytomedicine; 2014 Oct; 21(12):1717-24. PubMed ID: 25442282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.